Feature | June 10, 2014

Real-Time Radiation Monitoring Reduces Patient, Cardiologist Exposure

RadiCure study evaluates device that beeps upon radiation exposure

June 10, 2014 — A real-time monitoring device that beeps in the presence of high doses of radiation can help reduce patient and interventional cardiologist exposure to radiation during cardiac catheterization, according to results of the RadiCure study presented as a late-breaking clinical trial at the Society for Cardiovascular Angiography and Interventions (SCAI) 2014 scientific sessions in Las Vegas.

Radiation exposure during cardiac catheterization can place both the patient and the physician at risk. Advances in imaging equipment have helped reduce patient exposure, but physician exposure is typically only measured months later. In the study presented at SCAI, researchers monitored physician and patient radiation exposure using a real-time, personal radiation monitoring device called the Bleeper Sv. The device sounds every 15 minutes in response to normal background radiation and increases its beep rate as radiation exposure increases.

For the study, 505 patients undergoing left cardiac catheterization procedures were randomized to use or not use the monitoring device. Procedure times and patient characteristics were comparable in both study groups. Following the procedure, patient and interventional cardiologist radiation exposure was measured.

Researchers found that compared to the control group, use of the monitoring device led to a significant decrease in operator exposure [0.9 (0.4-1.7) vs 1.4 (0.6-2.5) mrem, p<0.001 for the first operator and 0.5 (0.2-1.0) vs 0.7 (0.4-1.4) mrem, p<0.001 for the second operator]. Patient radiation exposure did not differ significantly between the two groups; however, there was a trend for lower Air Kerma and Dose Area Product radiation in the Bleeper Sv group [0.855 (0.58-1.507) vs 0.989 (0.610-1.802) Gray, p=0.153 and 76.68 (52.98-133.53) vs 84.61 (55.37-161.20) Gray*cm2, p=0.125, respectively].

“Use of a personal radiation monitoring device that provides auditory feedback helps reduce both the patient and the interventional cardiologist’s exposure,” said Georgios Christopoulos, M.D., research fellow at VA North Texas Health Care System and the University of Texas Southwestern Medical Center.

“The device allows for immediate reaction that can limit exposure, unlike current monitoring that physicians undergo months after exposure,” said Emmanouil Brilakis, M.D., Ph.D., FSCAI, director of the cardiac catheterization laboratories at VA North Texas Health Care System, associate professor of medicine at the University of Texas Southwestern Medical Center and the study’s principal investigator.

For more information: www.scai.org

Related Content

Teleflex Launches Next-Generation Sympro Elite and Expro Elite Snares
Technology | Cath Lab | February 07, 2018
Teleflex Inc. has announced 510(k) clearance by the U.S. Food and Drug Administration (FDA) and U.S. commercial launch...
SCAI Advocacy Committee Highlights Reimbursement Reform Efforts in 2017
News | Cath Lab | January 30, 2018
The Society for Cardiovascular Angiography and Interventions (SCAI) highlighted the efforts of its Advocacy Committee...
IAC Releases Cardiovascular Catheterization Accreditation Program
News | Cath Lab | January 25, 2018
January 25, 2018 – The Intersocietal Accreditation Commission (IAC) announced the release of its Cardiovascular Cathe
Videos | Cath Lab | January 04, 2018
Bernadette Speiser, BSN, MSN, CCRN, RCIS, a cardiac cath/EP nurse at Palo Alto Veterans Hospital, Palo Alto, Calif.,
FDA Initiates Class I Recall of Sterilmed Reprocessed Agilis Steerable Introducer Sheath
News | Cath Lab | January 04, 2018
The U.S. Food and Drug Administration (FDA) announced a Class I recall of Sterilmed’s Agilis Steerable Introducer...
The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA atherectomy system. Athar Ansari, M.D.

The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA system. 

Feature | Cath Lab | November 24, 2017 | Athar Ansari, M.D., FACC
As debates about the current state and future of healthcare rage in Congress, the media and healthcare settings acros
Videos | Cath Lab | November 08, 2017
Juan Granada, M.D., Cardiovascular Research Foundation president and chief executive officer, shares his insights on
Results of the ORBITA study found no difference in exercise time after six weeks in patients with stable angina who received percutaneous coronary intervention (PCI) versus a placebo treatment. TCT 2017
Feature | Cath Lab | November 06, 2017
November 6, 2017 – Results from ORBITA, a prospective multi-center randomized blinded placebo-controlled study, found
Culprit Lesion-Only PCI Improves Outcomes for Cardiogenic Shock Patients Compared to Multivessel PCI
News | Cath Lab | November 01, 2017
November 1, 2017 — Results from the prospective, randomized, multicenter CULPRIT-SHOCK trial found an initial strateg
Overlay Init